Boston Scientific (NYSE:BSX) today announced the acquisition of Obsidio and its blood vessel embolization material technology.
The financial details of the deal were not disclosed. Obsidio develops gel embolic material (GEM) technology that is used for the embolization of blood vessels in the peripheral vasculature. It is a semi-solid, gel-link material packaged in a ready-to-use form to reduce the preparation time needed for embolization procedures.
The GEM agent is delivered through a catheter and enables controlled placement within unique patient anatomy. It conforms to the targeted vasculature to immediately create a barrier.
“The GEM technology combines benefits of currently available embolics, such as precise control of a solid and malleability of a liquid, to create a unique technology that offers procedural efficiency and a more personalized therapy for patients,” said Peter Pattison, president of interventional oncology and embolization in Boston Scientific’s peripheral interventions business. “This acquisition strengthens our interventional oncology and embolization portfolio with a differentiated solution for physicians and their patients suffering from hemorrhages, cancer and other debilitating conditions.”
Boston Scientific said the transaction is expected to be immaterial to its GAAP and adjusted earnings per share in 2022.
Shares in BSX were virtually unchanged in afternoon trading. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — was up slightly.
